Regen BioPharma, Inc. (OTCMKTS:RGBP – Get Free Report) saw a significant drop in short interest in the month of October. As of October 15th, there was short interest totaling 138,853 shares, a drop of 53.3% from the September 30th total of 297,566 shares. Based on an average daily volume of 7,295,221 shares, the short-interest ratio is presently 0.0 days.
Regen BioPharma Stock Performance
Regen BioPharma has a 52-week low of $0.00 and a 52-week high of $0.02.
About Regen BioPharma
Regen BioPharma, Inc is a biotechnology company focused on developing regenerative medicine and immunotherapy applications. The company has historically described its work as targeting conditions involving bone marrow failure, cancer and immune-system dysfunction.
Its reported research programs have included HemaXellerate, an investigational approach intended to support the restoration of blood-forming cells, as well as programs involving cancer vaccines, immune modulation and the NR2F6 biological pathway.
Further Reading
- Five stocks we like better than Regen BioPharma
- L3Harris Stock Took a Beating—Is a 20% Rebound Next?
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
Receive News & Ratings for Regen BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regen BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
